KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBT Margin (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed EBT Margin for 18 consecutive years, with 37.51% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin rose 7405.0% year-over-year to 37.51%; the TTM value through Mar 2026 reached 6.34%, up 683.0%, while the annual FY2025 figure was 0.17%, 8.0% up from the prior year.
  • EBT Margin hit 37.51% in Q1 2026 for Ionis Pharmaceuticals, down from 75.38% in the prior quarter.
  • Across five years, EBT Margin topped out at 156.09% in Q4 2024 and bottomed at 119.44% in Q1 2024.
  • Average EBT Margin over 5 years is 36.38%, with a median of 41.11% recorded in 2023.
  • Year-over-year, EBT Margin plummeted -45399bps in 2022 and then surged 15718bps in 2024.
  • Ionis Pharmaceuticals' EBT Margin stood at 29.19% in 2022, then surged by 96bps to 1.08% in 2023, then skyrocketed by 14535bps to 156.09% in 2024, then plummeted by -52bps to 75.38% in 2025, then plummeted by -150bps to 37.51% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 37.51%, 75.38%, and 81.93% for Q1 2026, Q4 2025, and Q3 2025 respectively.